NBIX catalyst calendar

NEUROCRINE BIOSCIENCES INC

Upcoming catalysts
17
Cash runway
Cash generating
Cash & investments
$332M
Phase 3 programs
19

NEUROCRINE BIOSCIENCES INC is tracked here for clinical trial milestones, SEC filings and earnings dates. Focus area: Biological Products, (No Diagnostic Substances).

The next scheduled catalyst is Next quarterly earnings (projected) on October 24, 2026, a projected date rather than a confirmed one. There are 17 upcoming events on record.

NEUROCRINE BIOSCIENCES INC generates cash from operations, so a burn-based runway figure does not apply.

Across 67 concluded trials, 82% reached completion rather than being terminated or withdrawn.

Upcoming catalysts

DateEventTypePhase
October 24, 2026 est. Next quarterly earnings (projected) Earnings —
February 15, 2027 Efficacy, Safety, and Tolerability of NBI-1065890 Versus Placebo in Adults With Tardive Dyskinesia Trial Milestone Phase 2
July 15, 2027 NBI-1065845-MDD3026: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) Trial Milestone Phase 3
July 15, 2027 Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) Trial Milestone Phase 3
July 15, 2027 NBI-1065845-MDD3025: Study to Assess the Efficacy and Safety of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) Trial Milestone Phase 3
August 15, 2027 Evaluation of NBI-1117570 in Inpatient Adults With Schizophrenia Trial Milestone Phase 2
October 15, 2027 NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia Trial Milestone Phase 3
November 15, 2027 NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia Trial Milestone Phase 3
February 15, 2028 An Assessment of Efficacy, Safety, and Pharmacokinetics of NBI-1117568 in Adults With Bipolar I Disorder With Current Mania Trial Milestone Phase 2
March 16, 2028 Efficacy, Safety, Tolerability, and Pharmacokinetics of NBIP-01435 in Adult Participants With Classic Congenital Adrenal Hyperplasia (CAH) Trial Milestone Phase 2
April 15, 2028 Long-term Study to Evaluate Safety and Tolerability of Valbenazine in Participants With Chorea Associated With Huntington Disease in Canada Trial Milestone Phase 3
May 15, 2028 Evaluation of NBI-1117567 in Participants With Mild to Moderate Alzheimer's Disease (AD) Taking a Background Acetylcholinesterase Inhibitor Trial Milestone Phase 2
June 15, 2028 A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor Trial Milestone Phase 4
July 15, 2028 A Study to Evaluate the Maintenance Effect of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) Trial Milestone Phase 3
May 15, 2029 Long-Term Study to Assess the Safety and Tolerability of NBI-1065845 as an Adjunctive Treatment in Participants With Major Depressive Disorder (MDD) Trial Milestone Phase 3
July 15, 2029 Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia Trial Milestone Phase 3
December 15, 2031 NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia Trial Milestone Phase 3

Track NBIX alongside other companies. Add it to a watchlist and see every catalyst on one calendar.

Open NBIX in the tracker

Recent history

DateEventTypePhase
September 28, 2026 8-K filed: Leadership change Corporate —
July 30, 2026 Quarterly results filed (8-K) Earnings —
May 28, 2026 8-K filed: Leadership change Corporate —
May 18, 2026 8-K filed: Material agreement, Acquisition completed, Reg FD disclosure Corporate —
May 5, 2026 Quarterly results filed (8-K) Earnings —
April 6, 2026 8-K filed: Material agreement Corporate —
February 11, 2026 Quarterly results filed (8-K) Earnings —
November 24, 2025 8-K filed: Leadership change Corporate —
November 12, 2025 Extension Study to Evaluate How Safe and Tolerable NBI-921352 is as an Adjunctive Therapy for Participants With SCN8A-DEE Trial Milestone Phase 2
November 5, 2025 Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease Trial Milestone Phase 3
October 28, 2025 Quarterly results filed (8-K) Earnings —
October 16, 2025 Study to Assess the Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Dyskinesia Due to Cerebral Palsy Trial Milestone Phase 3
July 30, 2025 Quarterly results filed (8-K) Earnings —
July 25, 2025 A Study to Evaluate the Efficacy and Safety of NBI-1070770 in Adults With Major Depressive Disorder Trial Milestone Phase 2
May 30, 2025 8-K filed: Leadership change Corporate —
May 22, 2025 8-K filed: Leadership change Corporate —
May 5, 2025 Quarterly results filed (8-K) Earnings —
February 4, 2025 Journey Study: Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as Adjunctive Treatment for Schizophrenia Trial Milestone Phase 3
January 27, 2025 Extension Study to Evaluate NBI-827104 in Pediatric Participants With Epileptic Encephalopathy With Continuous Spike-and-Wave During Sleep Trial Milestone Phase 2
December 27, 2024 Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia Trial Milestone Phase 4
October 30, 2024 VY-AADC02 for Parkinson's Disease With Motor Fluctuations (RESTORE-1) Trial Milestone Phase 1
July 10, 2024 Efficacy, Safety, Tolerability, and Pharmacokinetics of NBI-1117568 in Adults With Schizophrenia Trial Milestone Phase 2
June 28, 2024 Study to Evaluate the Efficacy, Safety, and Tolerability of Luvadaxistat in Participants With Cognitive Impairment Associated With Schizophrenia Trial Milestone Phase 2
March 11, 2024 Extension Study to Evaluate the Safety and Tolerability of NBI-921352 When Used With Anti-seizure Medications in Adults With Focal Onset Seizures Trial Milestone Phase 2
January 10, 2024 Study to Assess the Efficacy and Safety of NBI-1065845 in Adults With Major Depressive Disorder (MDD) Trial Milestone Phase 2
November 8, 2023 Study to Evaluate the Efficacy, Safety, and Tolerability of Valbenazine as an Adjunctive Treatment for Schizophrenia Trial Milestone Phase 3
August 21, 2023 A Study to Investigate How Effective, Safe and Tolerable the Drug NBI-921352 is When Used With Anti-seizure Medications in Adults With Focal Onset Seizures Trial Milestone Phase 2
July 19, 2023 Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia Trial Milestone Phase 3
July 7, 2023 Study to Evaluate the Efficacy and Safety of Once-Weekly Oral NBI-1065846 in the Treatment of Anhedonia in MDD Trial Milestone Phase 2
March 17, 2023 Study to Evaluate NBI-921352 as Adjunctive Therapy in Subjects With SCN8A Developmental and Epileptic Encephalopathy Syndrome (SCN8A-DEE) Trial Milestone Phase 2

About this data

Trial milestones come from the ClinicalTrials.gov v2 API, filings from SEC EDGAR, and financial figures from SEC XBRL company facts. Dates marked est. are projected rather than company-confirmed. This is an information tool, not investment advice — verify anything you act on against the linked primary source.

Last updated 2026-10-14.